Atossa Therapeutics, Inc.

NasdaqCM:ATOS Stock Report

Market Cap: US$96.3m

Atossa Therapeutics Valuation

Is ATOS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ATOS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$12.83
Fair Value
93.6% undervalued intrinsic discount
3
Number of Analysts

Below Fair Value: ATOS ($0.82) is trading below our estimate of fair value ($12.83)

Significantly Below Fair Value: ATOS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ATOS?

Key metric: As ATOS is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ATOS. This is calculated by dividing ATOS's market cap by their current book value.
What is ATOS's PB Ratio?
PB Ratio1.4x
BookUS$73.68m
Market CapUS$96.29m

Price to Book Ratio vs Peers

How does ATOS's PB Ratio compare to its peers?

The above table shows the PB ratio for ATOS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average2.1x
ALGS Aligos Therapeutics
2.1x14.2%US$102.2m
TARA Protara Therapeutics
1.1x0.5%US$91.0m
XBIT XBiotech
0.5xn/aUS$94.5m
ANIX Anixa Biosciences
4.9x15.1%US$101.7m
ATOS Atossa Therapeutics
1.4x51.7%US$96.3m

Price-To-Book vs Peers: ATOS is good value based on its Price-To-Book Ratio (1.4x) compared to the peer average (2.1x).

Price to Book Ratio vs Industry

How does ATOS's PB Ratio compare vs other companies in the US Biotechs Industry?

71 CompaniesPrice / BookEstimated GrowthMarket Cap
SLRN Acelyrin
0.4x23.8%US$204.66m
LYEL Lyell Immunopharma
0.3x-13.7%US$167.58m
CRGX CARGO Therapeutics
0.4x12.9%US$164.78m
NKTX Nkarta
0.3x-8.3%US$153.13m
ATOS 1.4xIndustry Avg. 1.6xNo. of Companies79PB01.63.24.86.48+
71 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: ATOS is good value based on its Price-To-Book Ratio (1.4x) compared to the US Biotechs industry average (1.7x).

Price to Book Ratio vs Fair Ratio

What is ATOS's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ATOS PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ATOS's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ATOS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.82
US$6.00
+631.6%
23.6%US$7.00US$4.00n/a3
Feb ’26US$0.84
US$6.00
+612.7%
23.6%US$7.00US$4.00n/a3
Jan ’26US$0.94
US$6.00
+535.5%
23.6%US$7.00US$4.00n/a3
Dec ’25US$1.30
US$5.83
+348.7%
22.5%US$7.00US$4.00n/a3
Nov ’25US$1.42
US$5.50
+287.3%
19.6%US$6.50US$4.00n/a3
Oct ’25US$1.46
US$5.50
+276.7%
19.6%US$6.50US$4.00n/a3
Sep ’25US$1.37
US$5.42
+295.4%
18.6%US$6.25US$4.00n/a3
Aug ’25US$1.29
US$5.42
+319.9%
18.6%US$6.25US$4.00n/a3
Jul ’25US$1.20
US$5.42
+351.4%
18.6%US$6.25US$4.00n/a3
Jun ’25US$1.30
US$5.33
+310.3%
17.7%US$6.00US$4.00n/a3
May ’25US$1.53
US$4.67
+205.0%
20.2%US$6.00US$4.00n/a3
Apr ’25US$2.00
US$4.58
+129.2%
18.0%US$5.75US$4.00n/a3
Mar ’25US$1.00
US$4.58
+358.3%
18.0%US$5.75US$4.00n/a3
Feb ’25US$0.84
US$4.88
+480.6%
17.9%US$5.75US$4.00US$0.842
Jan ’25US$0.88
US$4.88
+454.0%
17.9%US$5.75US$4.00US$0.942
Dec ’24US$0.76
US$4.75
+525.2%
15.8%US$5.50US$4.00US$1.302
Nov ’24US$0.68
US$4.83
+615.9%
12.9%US$5.50US$4.00US$1.423
Oct ’24US$0.74
US$4.83
+556.3%
12.9%US$5.50US$4.00US$1.463
Sep ’24US$0.80
US$4.63
+476.7%
13.5%US$5.25US$4.00US$1.372
Aug ’24US$1.10
US$4.63
+320.5%
13.5%US$5.25US$4.00US$1.292
Jul ’24US$1.26
US$4.63
+267.1%
13.5%US$5.25US$4.00US$1.202
Jun ’24US$0.92
US$4.63
+401.4%
13.5%US$5.25US$4.00US$1.302
May ’24US$0.60
US$4.75
+691.7%
15.8%US$5.50US$4.00US$1.532
Apr ’24US$0.72
US$4.75
+555.3%
15.8%US$5.50US$4.00US$2.002
Mar ’24US$0.73
US$5.00
+582.8%
20.0%US$6.00US$4.00US$1.002
Feb ’24US$0.80
US$5.00
+525.0%
20.0%US$6.00US$4.00US$0.842
Analyst Price Target
Consensus Narrative from 3 Analysts
US$6.00
Fair Value
86.3% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/10 06:56
End of Day Share Price 2025/02/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Atossa Therapeutics, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
Pooya HemamiEdison Investment Research
Emily BodnarH.C. Wainwright & Co.